16 assets in Fanconi Anemia

Therapeutic assets addressing Fanconi Anemia, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cyclophosphamide Fanconi Anemia	Porteus, Matthew, MD	P2/3	BBB (77)
Fludarabine Fanconi Anemia	Porteus, Matthew, MD	P2/3	BBB (76)
Busulfanum Fanconi Anemia	Masonic Cancer Center, University of Minnesota	P2/3	BBB (74)
Nivestim Fanconi Anemia	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	P2	BBB (74)
Alemtuzumab Fanconi Anemia	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	P2/3	BB (69)
Anti-Human T-Lymphocyte Immunoglobulin, Rabbit Fanconi Anemia	Porteus, Matthew, MD	P2	BB (69)
Tacrolimus Fanconi Anemia	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	P2	BB (68)
Melphalan Fanconi Anemia	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	P2	BB (66)
Metformin Fanconi Anemia	Ain Shams University	P3	BB (66)
Rituximab Fanconi Anemia	Porteus, Matthew, MD	P2	B (60)
Eltrombopag Fanconi Anemia	Julian Sevilla	P2	CCC (54)
Pbsc Fanconi Anemia	Children's Hospital Medical Center, Cincinnati	P2	CCC (53)
Briquilimab Fanconi Anemia	Porteus, Matthew, MD	P1/2	CCC (48)
fp-045 Fanconi Anemia	Foresee Pharmaceuticals Co., Ltd.	P1/2	CCC (48)
92.3% TO NMT 93.8% ETHANOL BY WEIGHT IN WATER Fanconi Anemia	Masonic Cancer Center, University of Minnesota	N/A	D (30)